ClinicalTrials.gg
CompletedNCT02155322Updated Aug 23, 2018Results posted

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

A Phase 2 interventional study of Pegylated Interferon Alfa-2b and Pegylated Interferon Alfa-2b in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.

Enrollment
8th of 14
33 · median 36
Started
2014
with 2 others
Phase 2
5 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 2, and was the 13th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing peginterferon alfa-2b in Melanoma as a file.
02

Study summary

This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Competent to self-administer the subcutaneous injections of PEG-IFN
  • documented involved regional lymph nodes of a primary cutaneous melanoma or unknown primary, meeting the study's staging criteria
  • Had the primary melanoma completely resected with adequate surgical margins and undergone operation for positive regional lymph nodes within 84 days of study start
  • Performance Status (ECOG PS) score of 0 or 1
  • Adequate hepatic, renal and bone marrow function as defined by study parameters obtained within 4 weeks prior to study start
  • For a female subject who is of or male participant with female sexual partner who is of childbearing potential, agree to use acceptable methods of for at least 2 weeks prior to study start and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations

Exclusion criteria

Exclusion Criteria:

  • Mucous membrane melanoma or ocular melanoma
  • Known to the components of study drug (including acetaminophen), or its analogs
  • Evidence of distant or non-regional lymph node or in-transit metastases
  • Disease that cannot be completely surgically resected
  • Prior within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ
  • Severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease
  • Hepatic decompensation
  • Thyroid dysfunction not responsive to therapy
  • Uncontrolled diabetes mellitus
  • Clinically active disease
  • Clinically active and/or uncontrolled infection, including active hepatitis
  • (HIV)
  • History of neuropsychiatric disorder requiring hospitalization
  • Actively abusing alcohol or drugs
  • Pregnant, lactating, or of and not using an effective means of
  • Medical condition requiring chronic systemic
  • Received any experimental therapy within 30 days prior to enrolling in this study
  • Received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for melanoma
  • Previously received interferon-α for any reason
  • Known serious hypersensitivity reaction to PEG-IFN or interferon alfa-2b
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    PEG-IFN

    6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)

    Biological: Pegylated Interferon Alfa-2b

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Adverse Events (AEs)

    An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose through follow-up; up to 13 months

  2. Percentage of Participants Discontinuing Study Drug Because of AEs

    An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose to last dose of treatment; up to 12 months

07

Results

Posted Apr 11, 2017

Participant flow

This study enrolled Russian participants with malignant melanoma who had undergone surgical resection and lymphadenectomy.

Participant flow — Overall Study
MilestonePEG-IFN
Started33
Treated32
Completed19
Not completed14
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Relapse/recurrence8
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryPercentage of Participants Experiencing Adverse Events (AEs)

An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose through follow-up; up to 13 months
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Adverse Events (AEs)
Percentage of participantsPEG-IFN
Percentage of Participants Experiencing Adverse Events (AEs)100.0
PrimaryPercentage of Participants Discontinuing Study Drug Because of AEs

An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose to last dose of treatment; up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing Study Drug Because of AEs
Percentage of participantsPEG-IFN
Percentage of Participants Discontinuing Study Drug Because of AEs3.1

Adverse events

Collected over From first dose through follow-up; up to 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN—5/32 (15.6%)32/32 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPEG-IFN
MONOCYTOSISBlood and lymphatic system disorders1/32
THROMBOCYTOPENIABlood and lymphatic system disorders1/32
CHOLECYSTITIS CHRONICHepatobiliary disorders1/32
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/32
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/32
TYPE 1 DIABETES MELLITUSMetabolism and nutrition disorders1/32
LEUKOCYTURIARenal and urinary disorders1/32
PROTEINURIARenal and urinary disorders1/32
URINARY TRACT PAINRenal and urinary disorders1/32
HAEMORRHAGEVascular disorders1/32
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPEG-IFN
PYREXIAGeneral disorders26/32
ALANINE AMINOTRANSFERASE INCREASEDInvestigations17/32
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations17/32
ASTHENIAGeneral disorders12/32
LEUKOPENIABlood and lymphatic system disorders9/32
THROMBOCYTOPENIABlood and lymphatic system disorders8/32
NAUSEAGastrointestinal disorders7/32
FATIGUEGeneral disorders7/32
INFLUENZA LIKE ILLNESSGeneral disorders7/32
NEUTROPENIABlood and lymphatic system disorders6/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PEG-IFN
Mean51.4 ± 12.86
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN
Female19
Male14
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Mar 2016, 19 months.

Results were first posted in Apr 2017, 1 year after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 19 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2014
First posted
Jun 4, 2014
StartActual
Aug 19, 2014
Primary completionActual
Mar 21, 2016
CompletionActual
Mar 21, 2016
Results first posted
Apr 11, 2017
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02155322
Responsible party
Sponsor
First posted
Jun 4, 2014
Start date
Aug 19, 2014
Primary completion
Mar 21, 2016
Completion
Mar 21, 2016
Results posted
Apr 11, 2017
Last update
Aug 23, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion